(82 days)
The Compass Bioscience Cardiac Markers Controls are to be used as a quality control material to assess the accuracy and precision of laboratory test methods used to measure the antigens and enzymes contained in the control. It is intended to validate the measurement of these analytes in patient samples.
Three levels of control are provided to allow the performance of the analyte test methods to be monitored within the clinically significant range.
The Compass Bioscience Cardiac Marker Calibration Control Set is used to verify the calibration of various test methods over the measurable range of the test.
Compass Bioscience Cardiac Markers Controls are supplied in three levels, 2 x 1 mL each level per box and as a four Level Calibration Verification set, 2 x 1 mL each level per box. The controls are supplied as a ready-to-use frozen liquid, requiring no reconstitution or dilution. They are prepared in a human EDTA plasma matrix fortified to target levels with human source material and reagent grade chemicals added at different concentrations to achieve the levels. Sodium Azide <0.1% has been added as preservative to inhibit microbial growth.
Here's a breakdown of the acceptance criteria and the study details for the Compass Bioscience Cardiac Markers Control and Calibration Verification Set, based on the provided text:
1. Table of Acceptance Criteria and Reported Device Performance:
| Acceptance Criteria Category | Specific Criteria | Reported Device Performance |
|---|---|---|
| Closed Vial Stability (-20°C) | Analyte recovery within ±(10% + highest allowable instrument/reagent imprecision) compared to initial test value after 1 year simulated storage | Passed: Achieved 1-year stability, based on accelerated stability studies by storing at 2-8°C to simulate -20°C conditions. Real-time testing is ongoing. |
| Closed and Opened Vial Stability (2-8°C) | Analyte recovery within ±(10% + % CVmethod) compared to Day 0 value after: - 30 days for CK-MB and Myoglobin - 14 days for Troponin I and BNP | Passed: Achieved 30-day stability for CK-MB and Myoglobin, and 14-day stability for Troponin I and BNP. Testing was conducted by measuring recovery at 7-day intervals. |
| Consistency Across Lots | No significant difference in performance across multiple lots of product. | Passed: Multiple lots of product were tested with no significant difference in performance. |
2. Sample Size Used for the Test Set and Data Provenance:
- Sample Size:
- For stability testing, "multiple lots of product" were used. The exact number of lots is not specified.
- For establishing assayed values, "multiple instruments and reagent lots" were used for calculations. The exact number is not explicitly stated.
- Data Provenance: The studies appear to be prospective as they involve real-time and accelerated stability testing of manufactured product lots. The data was generated in-house at Compass Bioscience and through interlaboratory studies. The country of origin of the data is not specified, but the manufacturing company (Compass Bioscience) is based in the USA.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts:
- The term "ground truth" isn't directly applicable in the context of control materials in the same way it would be for a diagnostic device identifying disease.
- For establishing "Assayed Values" (which serve as the reference for the control material), values were determined:
- From assays performed in the Compass Bioscience laboratory using three Triage® MeterPlus readers with specific Triage® panel tests.
- From interlaboratory data using instrument manufacturers' reagents.
- The text doesn't specify the "number of experts" or their "qualifications" in the traditional sense. Rather, it describes a process of analytical measurement using standard laboratory equipment and interlaboratory comparison.
4. Adjudication Method for the Test Set:
- No specific adjudication method (like 2+1, 3+1, none) is described for the test set or for establishing the assayed values. The values were derived from direct measurement and interlaboratory consensus on those measurements.
5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study Was Done:
- No, an MRMC comparative effectiveness study was not done. This type of study typically evaluates the improvement in human reader performance (e.g., radiologists interpreting images) with and without AI assistance for diagnostic tasks. This device is a quality control material, not a diagnostic imaging or interpretive AI device.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done:
- This question is not applicable to this device. The Compass Bioscience Cardiac Markers Control and Calibration Verification Set is a laboratory reagent (control material), not an algorithm or AI software. Its performance is evaluated based on its stability and its ability to provide consistent, established analyte levels when tested on laboratory instruments.
7. The Type of Ground Truth Used:
- As mentioned in point 3, the concept of "ground truth" as a diagnostic outcome is not strictly applicable.
- The "ground truth" for the control material itself is its established assayed values, which are derived from:
- Expert consensus/analytical measurement: Assays performed in-house using multiple instruments (Triage® MeterPlus readers) and specific test panels.
- Interlaboratory data: Data obtained from other laboratories using various instrument manufacturers' reagents.
- These values form the reference against which other measurements (e.g., during stability testing or routine QC) are compared.
8. The Sample Size for the Training Set:
- This question is not applicable to this device. As a control material, it does not use a "training set" in the context of machine learning or algorithm development. The "training" in this context would refer to the process of establishing the assayed values for the control material, as described in point 7.
9. How the Ground Truth for the Training Set Was Established:
- This question is not applicable as there is no "training set" for an algorithm. However, if we interpret "ground truth for the training set" as "how the assayed values for the control material were established," then:
- Assayed values for package inserts were established by:
- Performing assays in the Compass Bioscience laboratory using three Triage® MeterPlus readers with the Triage® Profiler S.O.B.™ Panel tests, the Triage® CardioProfiler Panel, and the Triage® Cardiac Panel.
- Collecting and analyzing interlaboratory data using various instrument manufacturers' reagents.
- Mean values were calculated from multiple instruments and reagent lots.
- Ranges were determined based on 2 SD - 3 SD of the overall mean values derived from stability and interlaboratory data.
- Assayed values for package inserts were established by:
{0}------------------------------------------------
Prepared: 8/29/2006 Submitted by: Establishment Address:
Evy K. Johnson Compass Bioscience 1850 Evergreen Street Duarte CA 91010 Phone: 626.359.96.45 FAX: 626.359.9645
NOV 2 2 2006
Establishment Registration Number: 2032652
Contact Person: Dr. Carter Grandjean, Director R&D
Proprietary Name: Cardiac Markers Control and Calibration Verification Set Common Name: Cardiac Markers Control and Calibration Verifier Controls Classification Name: Multi Analyte Controls, All Kinds (assayed and unassayed) 75 JJY Substantial Equivalence:
The Compass Bioscience Cardiac Markers Control and Calibration Set are supplied liguid in three or 4 levels and consist of a human plasma matrix containing preservatives to which reagent grade chemicals and human source antigens and enzymes have been added at different concentrations to achieve the levels. Assayed values are determined from in house and interlaboratory data.
The Compass Bioscience controls and calibration verifiers are substantially equivalent to other such controls and verifiers in general use, such as the Triage® Profiler S.O.B.™ (Shortness of Breath) Control and the Triage® Profiler S.O.B.™ (Shortness of Breath) Calibration Verification Controls which are supplied liquid in a two level control set and five level calibration set as a human EDTA plasma matrix with human source constituents and pure chemicals added by the manufacturer.
Description:
Compass Bioscience Cardiac Markers Controls are supplied in three levels, 2 x 1 mL each level per box and as a four Level Calibration Verification set, 2 x 1 mL each level per box. The controls are supplied as a ready-to-use frozen liquid, requiring no reconstitution or dilution. They are prepared in a human EDTA plasma matrix fortified to target levels with human source material and reagent grade chemicals added at different concentrations to achieve the levels. Sodium Azide <0.1% has been added as preservative to inhibit microbial growth.
Intended Use:
The Compass Bioscience Cardiac Markers Controls are intended for use as quality control materials to assess the accuracy and precision of assay procedures for the analytes included in the control. The Compass Bioscience Cardiac Marker Calibration Set is used to verify the calibration of various test methods over the measurable range of the test.
Technological Characteristics Compared to Predicate Devices:
The Compass Bioscience control products employ a similar matrix and constituent formulation to the equivalent predicate device listed above: human plasma matrix fortified with human source material,
{1}------------------------------------------------
reagent grade chemicals and azide as a preservative. The Compass Bioscience Control and Calibration Verification Set also have similar storage and stability requirements as the equivalent devices.
Performance Characteristics:
The closed vial stability claim made for this product is 1 year when stored at -20° C, based on accelerated stability studies.2 The Cardiac Markers control was stored at 2-8°C to simulate 1 year storage -20°C. An increase or decrease of >10% of analyte recovery compared to the initial test value ± the highest allowable instrument/reagent imprecision was used as the analyte failure criterion for determining shelf-life. Real time stability testing is ongoing on multiple lots of product.
The closed and opened vial stability claim for this product when stored at 2-8° C is 30 days for CK-MB and Myoglobin and 14 days for Troponin I and BNP. Real time testing was used to determine the closed and open vial refrigerated shelf life. The Cardiac Markers Control at 2 - 8° C and the recovery (vs. day 0) was measured in intervals of 7 days. The product passed stability if its recovery was within ±(10% + % CVmethod) after 44 days of storage at 2- 8°C.
Multiple lots of product were tested with no significant difference in performance.
The equivalent predicate device, Triage® Profiler S.O.B.™ Control claims a 2 year shelf life for storage at -20°C and a single use. The Bayer Healthcare LLC Liquid Cardiac Markers Plus Control claims a 20 day opened/closed vial stability at refrigerated (2-8°C) storage.
Assayed Values
Assay values for the package inserts were established from assays performed in the Compass Bioscience laboratory using three Triage® MeterPlus readers with the Triage® Profiler S.O.B.™ Panel tests, the Triage® CardioProfiler Panel, and the Triage® Cardiac Panel, and from interlaboratory data using instrument manufacturers' reagents. Mean values for the listed lots of controls were calculated from multiple instruments and reagent lots available at the time of assay. Ranges were determined based on 2 SD - 3SD of the overall mean values from stability and interlaboratory data.
2 L. Kennon, Stability Prediction Model, Journal of Pharmaceutical Sciences 53:7, 815-818, 1964.
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with three lines representing its body and wings. The eagle is positioned inside a circle with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
NOV 2 2 2006
Ms. Evy K. Johnson Compass Bioscience 1850 Evergreen Street Duarte, CA 91010
Re: K062593 Trade/Device Name: Cardiac Markers Control Cardiac Markers Calibration Verification Control Set Regulation Number: 21 CFR 862.1660 Regulation Name: Quality control material (assayed and unassayed) Regulatory Class: Class I Product Code: JJY Dated: August 30, 2006 Received: September 6, 2006
Dear Ms. Johnson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (sec above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements not the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
{3}------------------------------------------------
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Albert Gutt
Alberto Gutierrez, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
Indications for Use
510(k) Number (if known): K
Device Name: Cardiac Markers Control
Cardiac Markers Calibration Verification Control Set
Indications For Use:
The Compass Bioscience Cardiac Markers Controls are to be used as a quality control material to assess the accuracy and precision of laboratory test methods used to measure the antigens and enzymes contained in the control. It is intended to validate the measurement of these analytes in patient samples.
Three levels of control are provided to allow the performance of the analyte test methods to be monitored within the clinically significant range.
The Compass Bioscience Cardiac Marker Calibration Control Set is used to verify the calibration of various test methods over the measurable range of the test.
Prescription Use (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Carole Benam
Division Sign Off
Page 1 of 1
sion Sion-Of
Office of In Vitro Diagnostic Device Evaluation and Safety
§ 862.1660 Quality control material (assayed and unassayed).
(a)
Identification. A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed and unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls.(b)
Classification. Class I (general controls). Except when intended for use in donor screening tests, quality control materials (assayed and unassayed) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.